

Breast cancer

Stage I-III

ER+ HER 2-

LIDERA

ELIGIBILITY CRITERIA

- Pre or post-menopausal
- Prior definitive surgery and completed Chemotherapy (if given)
- No prior endocrine therapy
- ECOG 0-2

Arm A: Experimental Arm:

- Giredestrant 30 mg once a day.

Arm B Control Arm:

- SOC limited to either Tamoxifen or Aromatase inhibitors

Coordinator: Diana Omare -0727420410
Email: Diana.omare@aku.edu

HER 2+

ASTEFANIA

ELIGIBILITY CRITERIA

- ER/PR/PDL1 +/-
- Completed Neoadjuvant chemotherapy and surgery
- Residual invasive disease
- ECOG 0-1

Arm A: control arm:

- Placebo+Trastuzumab Emtansine.

Arm B: Experimental arm:

- Atezolizumab+Trastuzumab Emtansine

Coordinator: Yuashita Hussein-
0723122062
Email: Yuashita.hussein@aku.edu

HEREDERA

ELIGIBILITY CRITERIA

- Patients with ER+ advanced breast cancer.
- Previously untreated in the advanced setting.

Arm A : Control Arm.

- Phesgo.

Arm B: Experimental

- Phesgo+Giredestrant

Coordinator: Diana Omare-0727420410
Email: Diana.omare@aku.edu